Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $137
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $120 to $137.
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $120 to $137.